Livzon Pharmaceutical Group Inc. Livzon Pharmaceutical Group Inc.

Livzon Pharmaceutical Group Inc.

000513

Rangering i aksjer #4689
Livzon Pharmaceutical Group Inc., headquartered in Zhuhai, China, and... Livzon Pharmaceutical Group Inc., headquartered in Zhuhai, China, and established in 1985, is a biopharmaceutical enterprise operating across the entire spectrum of pharmaceutical activities, from research and development to manufacturing and commercialization. The company's operations encompass a diverse range of finished drug products, active pharmaceutical ingredients (APIs), and chemical intermediates, primarily serving the Chinese market while also engaging in international exports. Its pharmaceutical portfolio includes treatments such as Ilaprazole enteric coated tablets for duodenal ulcers and reflux esophagitis, Laprazole sodium injection for managing peptic ulcer bleeding, Leuprorelin Acetate Microspheres for injection, and Urofollitropin injection for anovulation and fertility support. Livzon also produces Perospirone Hydrochloride for schizophrenia, Anti-viral Granules targeting upper respiratory tract infections and influenza, and Shenqi Fuzheng Injection, which addresses general weakness, fatigue, spontaneous sweating, and vertigo, and provides supportive care for lung and stomach cancer patients. Beyond therapeutic drugs, Livzon Pharmaceutical Group develops and distributes a variety of diagnostic reagents. These include kits for detecting IgM/IgG antibodies to coronavirus, nucleic acid tests for human immunodeficiency virus type 1, antinuclear antibody test kits, interferon-gamma release assay kits, and rapid tests for mycoplasma pneumoniae IgM antibodies. The company's extensive offerings further extend to biochemical drugs, microbiological preparations, biologics, traditional Chinese medicine formulations, pharmaceutical raw materials, and antibiotics.
Aksjekurs
$3.90
Markedsverdi
$3.17B
Endring (1 dag)
-3.49%
Endring (1 år)
-25.88%
Land
CN
Handel Livzon Pharmaceutical Group Inc. (000513)

Kategori

Healthcare
EPS for Livzon Pharmaceutical Group Inc. (000513)
EPS per June 2026 TTM: $0.28
Ifølge de siste økonomiske rapportene og aksjekursen til Livzon Pharmaceutical Group Inc. er selskapets nåværende EPS (TTM) $0.28. Ved slutten av 2024 hadde selskapet en EPS på $0.31, en økning sammenlignet med EPS-en i 2023 som var $0.30.
EPS-historikk for Livzon Pharmaceutical Group Inc. fra 2001 til 2026
EPS ved slutten av hvert år
År EPS Endre
2026 (TTM) $0.28 -11.56%
2025 $0.32 5.73%
2024 $0.31 3.44%
2023 $0.30 0.34%
2022 $0.30 -1.07%
2021 $0.30 6.71%
2020 $0.28 40.33%
2019 $0.20 18.39%
2018 $0.17 -77.05%
2017 $0.73 466.90%
2016 $0.13 13.68%
2015 $0.11 15.74%
2014 $0.10 3.03%
2013 $0.10 14.63%
2012 $0.08 22.29%
2011 $0.07 -10.03%
2010 $0.08 -7.56%
2009 $0.08 842.53%
2008 $0.01 -89.04%
2007 $0.08 195.17%
2006 $0.03 80.54%
2005 $0.01 -11.83%
2004 $0.02 7.64%
2003 $0.02 45.37%
2002 $0.01 27.06%
2001 $0.01 0.00%
EPS for lignende selskaper eller konkurrenter
Selskap EPS EPS-forskjell Land
$6.55 2,213.50%
DE
$6.12 2,062.69%
DE
$0.72 155.51%
JP
$3.66 1,193.29%
CH
$0.53 88.59%
IN